Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer : Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) - Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 07:16pm CEST

TIME: 8 a.m.

EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) holds a meeting of the Arthritis Advisory Committee to discuss supplemental new drug applications 203214 supplement 17, for XELJANZ (tofacitinib) tablets and 208246 supplement 3, for XELJANZ XR (tofacitinib) extended release tablets submitted by Pfizer Inc., for the treatment of adult patients with active psoriatic arthritis.

DATE: August 3, 2017

LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center, the Great Room, Room 1503, Silver Spring, Md.

CONTACT: Philip Bautista, 301-796-9001, [email protected]

(c) 2006 Federal Information & News Dispatch, Inc., source Washington Daybook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
09/22 PFIZER : LabCentral to Open Next-Stage Facility for Growing Life Science Compani..
09/22 PFIZER : sues J&J over Remicade contracts
09/22 PFIZER : hits a snag in bid to jump-start Sutent`s flagging kidney cancer sales
09/21 PFIZER : New Immunoglobulins Study Findings Have Been Reported by Researchers at..
09/21 TRANSGENE : First Half-Year 2017 in Line with Our Objectives: All Clinical Progr..
09/21 PFIZER : National Sickle Cell Disease Poll of African Americans Dispels Long-Hel..
09/21 PFIZER : New Global Report Finds Majority of People at High Risk of Stroke Not B..
09/21 PFIZER : Phosplatin Therapeutics Announces Collaboration with Pfizer and Merck K..
09/21 PFIZER : National Sickle Cell Disease Poll of African Americans Dispels Long-Hel..
09/21 PFIZER : Presents Positive Pivotal Data for PF-05280014, an Investigational Bios..
More news
News from SeekingAlpha
09/22 YOUR DAILY PHARMA SCOOP : VanEck Vectors Biotech ETF, Esperion's Growth Potentia..
09/22 REDHILL BIOPHARMA : Highly De-Risked And Undervalued With A Deep Pipeline
09/22 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 22, 2017
09/21 Versartis' lead candidate VRS-317 flunks late-stage study; shares poised for ..
09/21 FDA's Woodcock says clinical trials system "broken"
Financials ($)
Sales 2017 52 717 M
EBIT 2017 19 912 M
Net income 2017 11 415 M
Debt 2017 23 788 M
Yield 2017 3,57%
P/E ratio 2017 19,16
P/E ratio 2018 16,62
EV / Sales 2017 4,51x
EV / Sales 2018 4,34x
Capitalization 214 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 37,9 $
Spread / Average Target 5,3%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER10.81%214 146
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
ROCHE HOLDING LTD.6.19%221 926
MERCK AND COMPANY11.75%178 914
SANOFI9.06%126 655